Analysis of Clinical Characteristics of Severe Pneumonia in Children Under Regular COVID-19 Outbreak Prevention and Control

Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v3i2.857

Linglong Lu, Hainan Xu, Dongping Huang, Shumei Peng

Guangdong Women and Children Hospital, Guangzhou 510010, Guangdong, China

Abstract

Objective — To investigate the clinical characteristics of severe pneumonia in childhood under the regular prevention and control of the COVID-19 epidemic in 2021. Methods — The clinical data of 132 children with severe pneumonia in our pediatric intensive care unit from January 1, 2021, to December 31, 2021, were counted. Results: There were 132 children diagnosed with severe pneumonia, including 49 with different underlying diseases: 12 with airway dysplasia, 13 with genetic metabolic diseases, 11 with congenital heart disease, 10 with malnutrition, 2 with drowning, and 1 with insecticide poisoning. Pathogenesis includes viruses: 33 cases of respiratory syncytial virus, 10 cases of influenza virus, 5 cases of cytomegalovirus, 3 cases of human rhinovirus, 2 cases of bocavirus, 1 case of adenovirus; 19 cases of Mycoplasma pneumoniae. Bacteria: 7 cases of Pseudomonas aeruginosa, 6 cases of Escherichia coli, 4 cases of Klebsiella pneumoniae, 3 cases of Staphylococcus aureus, including 1 case of methicillin-resistant Staphylococcus aureus, 2 cases of Streptococcus pneumoniae, 2 cases of Haemophilus influenzae, 2 cases of Acinetobacter baumannii, 1 case of Cattamora, and 1 case of Serratia marcescens. There were 6 cases of fungi, and 107 strains were detected, with a detection rate of 81.0%. Conclusion — Children with combined underlying diseases are more likely to develop severe pneumonia, such as malnutrition, congenital heart disease, airway malformations, and congenital inherited metabolic diseases. The top three pathogens are respiratory syncytial virus, Mycoplasma pneumoniae and influenza virus, and the top three bacterial infections are Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae. Among them, small infants are mainly respiratory syncytial virus, older children are mainly Mycoplasma pneumoniae, and those who are positive for bacterial infections are mostly mixed infections. After active standardized treatment, the cure rate of severe pneumonia in infants and children is high.

Keywords

infants and children, severe pneumonia, normalization, prevention and control, basic diseases

References

[1] SONG P, THEODORATOU E, LI X, et al. Causes of death in children younger than five years in China in 2015: an updated analysis[J]. J Glob Health, 2016, 6(2): 1-13.
[2] HE CH, LIU L, CHU Y, et al. National and subnational all cause and cause- specific child mortality in China, 1996-2015: a systematic analysis with implications for the Sustainable Development Goals[J]. Lancet Gl ob Health, 2017, 5(2): e186-e197.
[3] LAZZERINI M, SEWARD N, LUFESI N, etal. Mortality and its risk factors in Malawian children admitted to hospital with clinical pneumonia, 2001-12: a retrospective observational study[J]. Lancet Glob Health, 2016, 4(1): e57-e68.
[4] MCINTOSH K. Community-acquired pneumonia in children[J]. N Engl J Med, 2002, 346(6): 429-437.
[5] Huang Saihu, Meng Xiangying, Zhang Jianping, et al. Pathogenetic analysis and clinical characteristics of alveolar lavage fluid in children with severe pneumonia[J]. Chinese Journal of Applied Clinical Pediatrics, 2021, 36(4): 262-266.
[6] Taban EM, Richards GA.Observational study of therapeutic bronchoscopy in critical hypoxaemic ventilated patients with COVID-19 at Mediclinic Midstream Private Hospital in Pretoria, South Africa[J]. Afr J Thorac Crit Care Med, 2020, 26(4): 10.
[7] LEYENAAR JK, SHIEH MS, LAGU T, et al. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia[J]. Pediatr Infect Dis J, 2014, 33(4): 387-392.
[8] Wang Jinhua, Yang Jiawu, Ai Tao. Role of bendable bronchoscopy in the diagnosis and treatment of severe pneumonia in children[J]. Chinese Journal of Practical Pediatrics 2022, 37(2):121-123.
[9] PEDRAZA-BERNAL AM, RODRIGUEZ-MARTINEZ CE, ACUÑA-CORDERO R. Predictors of severe disease in a hospitalized population of childre with acute viral lower respiratory tract infections[J]. Journal of Medical Virology, 2016, 88(5): 754-759.
[10] National Health Commission of the People’s Republic of China, National Administration of Traditional Chinese Medicine. Diagnostic and treatment protocol for community-acquired pneumonia in children (2019 edition)[J]. Chinese Journal of Clinical Infectious Diseases, 2019, 12(1): 6-13.
[11] Seilesh Kadambari et al. Indirect effects of the covid-19 pandemic on child-hood infection in England: population based observational study. BMJ, 2022; 376.
[12] Sun Yongfeng, Yang Qin, Chen Min et al. Pathogenetic analysis of 2198 cases of pediatric severe pneumonia[J]. OURNAL OF GUIZHOU MEDICAL UNIVERSITY, 2020, 3(45): 345-349.
[13] Yang Ying. Distribution characteristics of pathogenic bacteria and changes in immune function in children with bacterial pneumonia[D]. Zhengzhou University, 2021.
[14] Xing Tianyu. Analysis of clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children[J]. EILONGJIANG SCIENCE, 2021, 12(22): 72-73.
[15] Peng Xiaohua, Wang Lihong. Clinical characteristics of pediatric severe pneumonia and analysis of risk factors for CPAP treatment[J]. Maternal and Child Health Care of China, 2018, 33(19): 4435-4437.
[16] Yang Chunru. Evaluation of the efficacy of blood purification in the treatment of pediatric severe pneumonia[J]. Journal of Clinical Medical, 2017, 4(80): 15766-15767.
[17] Fu Hongmin, Lu Quan. Focus on severe pneumonia: A little reflection on the development of combined respiratory and critical care medicine in children[J]. Chinese Journal of Practical Pediatrics, 2022, 2(37): 88-91.

Copyright © 2022 Linglong Lu, Hainan Xu, Dongping Huang, Shumei Peng

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License